Curevac NV Schedule 13D activist filings

MH-LT-Investments GmbH and Dr. Matthias Hothum have completed the exchange of all their CureVac N.V. shares for BioNTech SE securities, marking their exit as beneficial owners.

A group of reporting persons, including dievini Hopp BioTech holding GmbH & Co. KG, has completed the tender of all their CureVac N.V. shares to BioNTech SE through an exchange offer.

KfW has completed the tender of all its Common Shares in CureVac N.V. through an Exchange Offer, resulting in 0% beneficial ownership and the expected termination of the Shareholders' Agreement.

GSK plc has finalized the sale of all its common shares in CureVac N.V. through a recent Exchange Offer.

GSK plc's subsidiary, Glaxo Group Limited, has agreed to tender its 7.4% stake in CureVac N.V. into BioNTech SE's exchange offer.

Germany's state-owned KfW bank has agreed to tender its significant stake in CureVac N.V. to BioNTech SE, supporting an exchange offer that aims to acquire all outstanding shares and facilitate a post-offer reorganization.

Key CureVac N.V. stockholders, including dievini Hopp BioTech holding GmbH & Co. KG, have entered into a Tender and Support Agreement with BioNTech SE, committing to tender their shares into BioNTech's exchange offer and support the proposed acquisition and post-offer reorganization.